Li Wang, PhD1; Xiaoguang Li, PhD1; Zhaoxin Wang, PhD1; Michael P. Bancks, PhD2; Mercedes R. Carnethon, PhD3; Philip Greenland, MD3; Ying-Qing Feng, MD4; Hui Wang, MD, PhD1; Victor W. Zhong, PhD1
doi : 10.1001/jama.2021.9883
JAMA. 2021;326(8):704-716
Understanding population-wide trends in prevalence and control of diabetes is critical to planning public health approaches for prevention and management of the disease.
Jean M. Lawrence, ScD, MPH, MSSA1,2; Jasmin Divers, PhD3; Scott Isom, MS4; Sharon Saydah, PhD5; Giuseppina Imperatore, MD, PhD6; Catherine Pihoker, MD7; Santica M. Marcovina, PhD, ScD8; Elizabeth J. Mayer-Davis, PhD9; Richard F. Hamman, MD, DrPH10; Lawrence Dolan, MD11; Dana Dabelea, MD, PhD10,12,13; David J. Pettitt, MD14; Angela D. Liese, PhD15; for the SEARCH for Diabetes in Youth Study Group
doi : 10.1001/jama.2021.11165
JAMA. 2021;326(8):717-727
Changes in the prevalence of youth-onset diabetes have previously been observed.
Inbal Goldshtein, PhD1,2; Daniel Nevo, PhD3; David M. Steinberg, PhD3; Ran S. Rotem, ScD1,4; Malka Gorfine, PhD3; Gabriel Chodick, PhD1,2; Yaakov Segal, MD5
doi : 10.1001/jama.2021.11035
JAMA. 2021;326(8):728-735
Data on BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) effectiveness and safety in pregnancy are currently lacking because pregnant women were excluded from the phase 3 trial.
Allan J. Walkey, MD, MSc1; Anica Law, MD, MS1; Nicholas A. Bosch, MD, MSc1
doi : 10.1001/jama.2021.11048
JAMA. 2021;326(8):766-767
US Preventive Services Task Force
doi : 10.1001/jama.2021.12531
JAMA. 2021;326(8):736-743
An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes vary widely, perhaps because of differences in the definition of prediabetes or the heterogeneity of prediabetes. Diabetes is the leading cause of kidney failure and new cases of blindness among adults in the US. It is also associated with increased risks of cardiovascular disease, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis and was estimated to be the seventh leading cause of death in the US in 2017. Screening asymptomatic adults for prediabetes and type 2 diabetes may allow earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes.
Daniel E. Jonas, MD, MPH1,2; Karen Crotty, PhD, MPH1,3; Jonathan D. Y. Yun, MD, MPH4; Jennifer Cook Middleton, PhD1,5; Cynthia Feltner, MD, MPH1,5,6; Sian Taylor-Phillips, PhD, MPhys, MSc7; Colleen Barclay, MPH1,2; Andrea Dotson, MD, MSPH5; Claire Baker1,5; Casey P. Balio, PhD1,5; Christiane E. Voisin, MSLS1,5; Russell P. Harris, MD, MPH5,6
doi : 10.1001/jama.2021.10403
JAMA. 2021;326(8):744-760
Type 2 diabetes is common and is a leading cause of morbidity and disability.
Ian J. Barbash, MD, MS1; Jeremy M. Kahn, MD, MS2
doi : 10.1001/jama.2021.12484
JAMA. 2021;326(8):693-694
A. Jay Holmgren, PhD1; David Cutler, PhD2; Ateev Mehrotra, MD3
doi : 10.1001/jama.2021.12191
JAMA. 2021;326(8):695-696
William R. Smith, MD, PhD1,2; Paul S. Appelbaum, MD3,4
doi : 10.1001/jama.2021.12481
JAMA. 2021;326(8):697-698
Krista Lyn Harrison, PhD1,2
doi : 10.1001/jama.2021.13539
JAMA. 2021;326(8):699-700
Edward W. Gregg, PhD1; Tannaz Moin, MD, MBA, MSHS2,3
doi : 10.1001/jama.2021.12559
JAMA. 2021;326(8):701-703
Jason T. Alexander, MD1; Adam S. Cifu, MD1
doi : 10.1001/jama.2021.9855
JAMA. 2021;326(8):761-762
Alicia Ault
doi : 10.1001/jama.2021.11469
JAMA. 2021;326(8):687-689
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.12353
JAMA. 2021;326(8):692
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.13403
JAMA. 2021;326(8):692
Anita Slomski
doi : 10.1001/jama.2021.12645
JAMA. 2021;326(8):691
Anita Slomski
doi : 10.1001/jama.2021.13715
JAMA. 2021;326(8):691
Anita Slomski
doi : 10.1001/jama.2021.13716
JAMA. 2021;326(8):691
Rita Rubin, MA
doi : 10.1001/jama.2021.13034
JAMA. 2021;326(8):690
Rita Rubin, MA
doi : 10.1001/jama.2021.13728
JAMA. 2021;326(8):690
Rita Rubin, MA
doi : 10.1001/jama.2021.13729
JAMA. 2021;326(8):690
Jill Jin, MD, MPH1
doi : 10.1001/jama.2021.12606
JAMA. 2021;326(8):778
Eduardo C. Costa, PhD1; Gabriel G. Cucato, PhD2; Raphael M. Ritti-Dias, PhD3
doi : 10.1001/jama.2021.9759
JAMA. 2021;326(8):767-768
Azmi Rahman, BSc1; Sajeenth Vishnu K, BSc1
doi : 10.1001/jama.2021.9762
JAMA. 2021;326(8):768
Lauren Gurich, PharmD1; Anna Nelson, MD, MS1
doi : 10.1001/jama.2021.9765
JAMA. 2021;326(8):768-769
Mary M. McDermott, MD1; Dongxue Zhang, MS1
doi : 10.1001/jama.2021.9768
JAMA. 2021;326(8):769-770
Peter H. Brubaker, PhD1; Steven J. Keteyian, PhD2; Wesley J. Tucker, PhD3
doi : 10.1001/jama.2021.10052
JAMA. 2021;326(8):770
Benjamin J. R. Buckley, PhD1; Gregory Y. H. Lip, MD1; Dick H. J. Thijssen, PhD2
doi : 10.1001/jama.2021.10055
JAMA. 2021;326(8):770-771
Masatsugu Okamura, PT, MSc1; Shunsuke Taito, PT, PhD2; Shuhei Yamamoto, PT, PhD3
doi : 10.1001/jama.2021.10058
JAMA. 2021;326(8):771
Arik Bernard Schulze, MD1; Georg Evers, MD1; Michael Mohr, MD1
doi : 10.1001/jama.2021.10049
JAMA. 2021;326(8):771-772
Stephan Mueller, MA1; Bernhard Haller, Dr rer nat2; Martin Halle, MD1; for the OptimEx-Clin Study Group
doi : 10.1001/jama.2021.10061
JAMA. 2021;326(8):772-773
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟